NCT00093353 2026-04-14
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
Clinical Trials
79 trialsNCT00509353 2026-04-14
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT06541262 2026-04-09
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT07375563 2026-01-29
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT07346157 2026-01-16
PNOC044
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT07334301 2026-01-12
BEACON2
University of Birmingham
Phase 1/2 Recruiting
NCT07318831 2026-01-06
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05400603 2025-12-26
Aflac-NBL-2002
Emory University
Phase 1 Recruiting
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07027748 2025-07-14
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03189706 2025-07-02
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT02308527 2024-05-14
BEACON
University of Birmingham
Phase 2 Active not recruiting
NCT00876993 2023-07-03
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Johns Hopkins All Children's Hospital
Phase 1 Completed
NCT01528046 2023-01-13
Metformin in Children With Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02035137 2022-06-08
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Completed
NCT01012609 2022-03-14
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01467986 2020-10-06
RIST-rNB-2011
University of Regensburg
Phase 2 Completed
NCT00984438 2019-11-25
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
Phase 1/2 Withdrawn
NCT01114555 2019-11-21
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01014767 2019-08-20
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Tufts Medical Center
Phase 3 Terminated
NCT01601535 2019-07-31
Study of MLN8237 in Combination With Irinotecan and Temozolomide
New Approaches to Neuroblastoma Therapy Consortium
Phase 1/2 Completed
NCT01576692 2018-11-15
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00671801 2018-11-13
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01086345 2018-07-03
Radiosurgery Plus Bevacizumab in Glioblastoma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT00003616 2018-06-27
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00006025 2018-06-27
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00890786 2018-05-02
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT00617539 2018-04-20
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Phase 2 Completed
NCT00389584 2017-11-06
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
University of California, Davis
Phase 1/2 Completed
NCT00644696 2017-07-06
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT02848794 2017-06-16
Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
The First People's Hospital of Lianyungang
Phase 1/2 Unknown
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00360828 2017-03-23
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00003134 2016-12-07
Irinotecan in Treating Patients With Recurrent Glioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00027612 2016-12-07
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01999270 2016-10-21
Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
Washington University School of Medicine
Phase 1 Completed
NCT01574092 2015-08-24
Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas
Hospital Sant Joan de Deu
Phase 2 Completed
NCT00003484 2015-04-23
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1 Completed
NCT01518413 2015-02-27
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Children's National Research Institute
Phase 1 Completed
NCT00005951 2014-08-22
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Duke University
Phase 1 Completed